LAUSR

1 Sadler JE, Budde U, Eikenboom JCJ et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–14. 2 Flood VH, Gill JC, Christopherson PA et al. Comparison of type I, type III, and type VI collagen binding assays in diagnosis of VWD. J Thromb Haemost 2012; 10: 1425–32. 3 Flood VH, Gill JC, Christopherson PA et al. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost 2012; 10: 1417–24. 4 Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in plateletand collagen-binding defects in type 2M von Willebrand disease. Haemophilia 2013; 19: 590–4. 5 Riddell AF, Gomez K, Millar CM et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114: 3489–96. 6 Legendre P, Navarrete A-M, Rayes J et al. Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood 2013; 121: 2135–43. 7 Fidalgo T, Salvado R, Corrales I et al. Genotype–phenotype correlation in a cohort of Portuguese patients comprising the entire spectrum of VWD types: impact of NGS. Thromb Haemost 2016; 116: 17– 31. 8 Penas N, P erez-Rodr ıguez A, Torea JH et al. Von, Willebrand disease R1374C: Type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia). Am J Hematol 2005; 80: 188–96. 9 Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol 2009; 121: 145–53. 10 Castaman G, Giacomelli SH, Jacobi PM et al. Reduced von Willebrand factor secretion is associated with loss of WeibelPalade body formation. J Thromb Haemost 2012; 10: 951–8.